摘要
目的观察艾司洛尔与胺碘酮治疗射血分数中间值心力衰竭(HFmrEF)患者快速房颤的临床效果。方法选取我院2017年1月至2019年12月收治并发HFmrEF的快速房颤患者90例,随机分为两组,每组45例。胺碘酮组给予胺碘酮静脉注射,艾司洛尔组给予艾司洛尔静脉注射。对比治疗期间两组心室率、疗效及血脑钠尿肽(BNP)。结果治疗后艾司洛尔组较胺碘酮组心室率下降的幅度有统计学意义(P<0.05, P<0.01),尤以用药(5~15)min时最为显著(P<0.01)。两组总有效率无统计学差异,但在治疗(5~30)min有效率差异有统计学意义(P<0.05, P<0.01),尤以治疗(5~15)min的差别最为显著(P<0.01)。胺碘酮组和艾司洛尔组的平均起效时间为(32±6)min和(10±4)min。治疗后,艾司洛尔组BNP较治疗前显著下降(P<0.05)。结论静脉注射艾司洛尔和胺碘酮可安全、有效地治疗并发HFmrEF的快速房颤患者,但前者更快速、更有效。
AIM To observe the clinical effects of esmolol and amiodarone in the treatment of rapid atrial fibrillation(AF) in patients with midrange ejection fraction heart failure(HFmrEF). METHODS Ninety cases of rapid AF with HFmrEF in our hospital from January 2017 to December 2019 were randomly divided into two groups of 45 patients. The control group was given intravenous amiodarone and the study group was administered intravenous esmolol. The ventricular rate, efficacy and blood B-type natriuretic peptide(BNP) were compared between the two groups. RESULTS After treatment, the decrease of ventricular rate in the study group was statistically significant compared with that in the control group(P < 0.05, P < 0.01), especially during the treatment of(5-15) minutes(P < 0.01). There was no statistical difference in the total effective rate between the two groups, but the difference was statistically significant during the treatment of(5-30) minutes(P < 0.05, P < 0.01), especially during the treatment of(5-15) minutes(P < 0.01). The average onset time of control group and study group was(32 ± 6) min and(10 ± 4) min. After treatment, BNP in the study group decreased significantly(P < 0.05). CONCLUSION Intr avenous esmolol and amiodarone are both safe and effective in the treatment of rapid AF with HFmrEF,but esmolol is faster and more effective.
作者
杨晶
邵丽杰
贺显建
门满库
马园
YANG Jing;SHAO Li-jie;HE Xian-jian;MEN Man-ku;MA Yuan(Department of Cardiology,PLA 986 Hospital,Xi’an 710054,Shaanxi,China;Department of Anesthesiology,PLA 986 Hospital,Xi’an 710054,Shaanxi,China;Graduate School,Xi’an Medical University,Xi’an 710021,Shaanxi,China)
出处
《心脏杂志》
CAS
2020年第2期156-159,163,共5页
Chinese Heart Journal
基金
西京医院学科助推计划自由探索项目(XJZT18ML57)。
